|
Synonyms: BPS 804 | BPS804
Compound class:
Antibody
Comment: BPS-804 is a fully human investigational monoclonal antibody targeting sclerostin (SOST), being developed by Mereo BioPharma and which is designed to improve bone density. BPS-804 is one of the clinical assets acquired from Novartis, in exchange for equity in Mereo BioPharma.
Development of anti-sclerostin antibodies by Novartis is claimed in patent WO2009047356 [2], although we cannot definitively conclude that BPS-804 is claimed within that patent application. The potential of sclerostin as a therapeutic target in bone diseases is reviewed by Lewiecki (2014) [3]. |
| No information available. |
Summary of Clinical Use  |
| BPS-804 has completed Phase 2 clinical trial in patients with osteogenesis imperfecta, a.k.a. brittle bone syndrome (NCT01417091). Development for hypophosphatasia and postmenopausal osteoporosis has been discontinued. The agent has both U.S. and EU orphan drug designation for osteogenesis imperfecta. |
| Mechanism Of Action and Pharmacodynamic Effects |
| BPS-804 binds to sclerostin, an osteocyte protein which normally inhibits Wnt signalling and decreases bone formation by osteoblasts [1,5] as part of the regulatory system controlling bone mass equilibrium. Neutralisation of sclerostin activity leads to improved bone formation in animal models, as reported for another anti-sclerostin antibody, romosozumab [4,6]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01417091 | Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta | Phase 2 Interventional | Novartis | ||
